Shinya Kimura

Summary

Affiliation: Saga University
Country: Japan

Publications

  1. ncbi request reprint AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer
    Shinya Kimura
    Saga University, Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine, Department of Internal Medicine, Saga University, 5 1 1 Nabeshima, Saga, Japan
    Curr Opin Investig Drugs 11:1442-9. 2010
  2. ncbi request reprint The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib
    Kentaro Iwanaga
    Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan
    Intern Med 51:2771-4. 2012
  3. doi request reprint Ever-advancing chronic myeloid leukemia treatment
    Shinya Kimura
    Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5 1 1 Nabeshima, Saga, 849 8501, Japan
    Int J Clin Oncol 19:3-9. 2014
  4. pmc Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
    Seiichi Okabe
    First Department of Internal Medicine, Tokyo Medical University, Tokyo 160 0023, Japan
    Cancer Cell Int 13:32. 2013
  5. pmc Development of a novel, fully-automated genotyping system: principle and applications
    Shun ichi Suzuki
    Arkray Inc, Kyoto 602 0008, Japan
    Sensors (Basel) 12:16614-27. 2012
  6. doi request reprint Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA
    Tomomi Nakamura
    Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
    J Thorac Oncol 7:1369-81. 2012
  7. doi request reprint A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA
    Tomomi Nakamura
    Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
    J Thorac Oncol 6:1639-48. 2011
  8. doi request reprint Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients
    Aya Tanaka
    Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5 1 1 Nabeshima, Saga 849 8501, Japan
    Lung Cancer 75:89-94. 2012
  9. doi request reprint Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
    Hitomi Umeguchi
    Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849 8501, Japan
    Oncol Rep 33:391-6. 2015
  10. pmc Correlation between plasma DNA and tumor status in an animal model
    Naoko Sueoka-Aragane
    Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
    PLoS ONE 9:e111881. 2014

Collaborators

Detail Information

Publications27

  1. ncbi request reprint AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer
    Shinya Kimura
    Saga University, Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine, Department of Internal Medicine, Saga University, 5 1 1 Nabeshima, Saga, Japan
    Curr Opin Investig Drugs 11:1442-9. 2010
    ..Thus, AT-9283 has potential as a therapeutic agent in several patient populations through its different inhibitory activities...
  2. ncbi request reprint The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib
    Kentaro Iwanaga
    Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan
    Intern Med 51:2771-4. 2012
    ..Therefore, the examination of EGFR mutation status is important in order to determine the appropriate treatment, even in patients with non-adenocarcinoma...
  3. doi request reprint Ever-advancing chronic myeloid leukemia treatment
    Shinya Kimura
    Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5 1 1 Nabeshima, Saga, 849 8501, Japan
    Int J Clin Oncol 19:3-9. 2014
    ..Moreover, it was recently reported that some CML patients who achieved sustained complete molecular response could stop TKI. CML may become the first human cancer to be conquered solely with oral medicines...
  4. pmc Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
    Seiichi Okabe
    First Department of Internal Medicine, Tokyo Medical University, Tokyo 160 0023, Japan
    Cancer Cell Int 13:32. 2013
    ..However, resistance to imatinib mediated by mutations in the BCR-ABL domain has become a major problem in the treatment of these patients...
  5. pmc Development of a novel, fully-automated genotyping system: principle and applications
    Shun ichi Suzuki
    Arkray Inc, Kyoto 602 0008, Japan
    Sensors (Basel) 12:16614-27. 2012
    ..The i-densy™ is a useful tool for optimization of anticancer drug therapy and can contribute to personalized medicine...
  6. doi request reprint Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA
    Tomomi Nakamura
    Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
    J Thorac Oncol 7:1369-81. 2012
    ..Although retreatment often prolongs survival, how to select the appropriate population for retreatment has not been clarified...
  7. doi request reprint A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA
    Tomomi Nakamura
    Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
    J Thorac Oncol 6:1639-48. 2011
    ..However, half of the patients acquire resistance because of the gatekeeper T790M mutation. Noninvasive mutation detection system is desired considering the difficulty in obtaining tissue specimens during disease progression...
  8. doi request reprint Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients
    Aya Tanaka
    Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5 1 1 Nabeshima, Saga 849 8501, Japan
    Lung Cancer 75:89-94. 2012
    ..These results suggest that MET FISH is a potential prognostic factor and coexistence of MET FISH with EGFR mutations signifies worse prognosis...
  9. doi request reprint Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
    Hitomi Umeguchi
    Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849 8501, Japan
    Oncol Rep 33:391-6. 2015
    ..Considering these results, assessing HGF and T790M using peripheral blood could be useful for monitoring mechanisms of acquired resistance to EGFR-TKIs...
  10. pmc Correlation between plasma DNA and tumor status in an animal model
    Naoko Sueoka-Aragane
    Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
    PLoS ONE 9:e111881. 2014
    ..We present a novel animal model with systemic metastasis with human lung cancer cells. The amount of tumor derived DNA would be related with tumor volume and tumor progression such as metastasis. ..
  11. doi request reprint A fully integrated, automated and rapid detection system for KRAS mutations
    Norio Ureshino
    Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, and Department of Medical Oncology, Saga Prefectural Hospital, Saga 849 8501, Japan
    Oncol Rep 26:609-13. 2011
    ..These findings characterize the QP method as an accurate and rapid detection system for KRAS mutations...
  12. doi request reprint ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia
    Mariko Yoshimura
    Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5 1 1 Nabeshima, Saga, 849 8501, Japan
    Int J Hematol 100:611-4. 2014
    ..Our observation in one patient receiving multiple TKIs suggests that nilotinib may be safer than imatinib or dasatinib in avoiding the development or exacerbation of PAP...
  13. pmc Severe eosinophilic pneumonia presenting during gemcitabine adjuvant chemotherapy
    Tomomi Yakabe
    Department of Community Medical Support Institute, Saga University, Saga, Japan
    World J Surg Oncol 11:167. 2013
    ..Physicians should be cognizant of the possible association of serious pulmonary toxicity with gemcitabine treatment. A delay in diagnosis and treatment could lead to a fatal outcome. ..
  14. doi request reprint NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase II{alpha} and DNA-dependent protein kinase
    Takashi Hisatomi
    Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
    Blood 117:3575-84. 2011
    ..These results suggest that NK314 is a dual inhibitor of Top2α and DNA-PK. Because ATL cells express a high amount of DNA-PKcs, NK314 as a dual molecular targeting anticancer agent is a potential therapeutic tool for treatment of ATL...
  15. pmc Development of lymphoproliferative diseases by hypoxia inducible factor-1alpha is associated with prolonged lymphocyte survival
    Eisaburo Sueoka
    Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
    PLoS ONE 8:e57833. 2013
    ..These results suggest that HIF-1alpha itself is not oncogenic but it may play an important role in lymphomagenesis mediated through the prolonged survival of lymphocytes in this transgenic mouse model...
  16. ncbi request reprint [Efficacy of aprepitant for quality of life of outpatients receiving moderately emetogenic chemotherapy]
    Sakiko Mochinaga
    Dept of Pharmacy, Saga University Hospital, and Dept of Surgery, Faculty of Medicine, Saga University
    Gan To Kagaku Ryoho 39:933-7. 2012
    ..Our results suggest that nausea, vomiting, loss of appetite, and QOL disturbance occur in many outpatients undergoing MEC, and that concomitant therapy with 3 drugs including aprepitant can improve symptoms and QOL of these patients...
  17. ncbi request reprint Effects of reduced dose intensity of modified FOLFOX6 in patients with metastatic or recurrent colorectal cancer
    Sakiko Mochinaga
    Department of Pharmacy, Saga University Hospital, Saga, Japan
    Oncol Res 19:511-8. 2011
    ..These findings suggested that reductions in ARDI of mFOLFOX6 therapy for metastatic or recurrent colorectal cancer due to treatment delays and dose reductions in response to adverse events do not necessarily lead to shortened TTF and OS...
  18. doi request reprint Uncommon case of chronic myeloid leukemia with multiple myeloma
    Masaru Ide
    Department of Hematology, Saga Prefectural Hospital Koseikan, Saga, Japan
    Int J Hematol 91:699-704. 2010
    ..The coexistence of CML and MM is an extremely uncommon event that has only been reported in 12 cases. We discuss the relationship between CML and MM...
  19. doi request reprint Monitoring with a non-invasive bioluminescent in vivo imaging system of pleural metastasis of lung carcinoma
    Seiji Matsumoto
    Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Kyoto, Japan
    Lung Cancer 66:75-9. 2009
    ..We established a MPE model and investigated the therapeutic effects of the administration of serial doses of docetaxel on intrathoracic disseminated foci using an in vivo image system (IVIS)...
  20. ncbi request reprint Disseminated Nocardiosis caused by Nocardia concava with acute respiratory failure and central nervous system involvement treated with linezolid
    Naomi Kobayashi
    Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan
    Intern Med 51:3281-5. 2012
    ..Linezolid should be considered as an alternative agent for treating disseminated nocardiosis because of its effective distribution to multiple sites...
  21. doi request reprint Comparative study of the anti-leukemic effects of imatinib mesylate, Glivec™ tablet and its generic formulation, OHK9511
    Masako Yokoo
    Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University
    Biol Pharm Bull 38:411-6. 2015
    ..Although the experiments performed herein were basic, the results suggest that physicians should consider using generic IM. ..
  22. ncbi request reprint A fully integrated and automated detection system for single nucleotide polymorphisms of UGT1A1 and CYP2C19
    Norio Ureshino
    Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
    Oncol Res 19:111-4. 2011
    ..These findings indicate that the QP method will enable point-of-care testing in clinical laboratories and patient-oriented therapy with its convenience and speed for patients who are treated with irinotecan or proton pump inhibitors...
  23. ncbi request reprint [Antiemetic effect of aprepitant in cancer patients receiving Cisplatin regimen]
    Tomomi Yakabe
    Dept of Surgery, Saga University
    Gan To Kagaku Ryoho 39:69-73. 2012
    ..These results suggest that APR is useful for nausea, vomiting, and appetite loss caused by CDDP, which is a highly emetic drug, and that such guideline-based antiemetic therapy might improve the quality of life of patients...
  24. ncbi request reprint Comparison of human herpes virus 8 related primary effusion lymphoma with human herpes virus 8 unrelated primary effusion lymphoma-like lymphoma on the basis of HIV: report of 2 cases and review of 212 cases in the literature
    Yutaka Kobayashi
    Division of Hematology and Oncology, Department of Internal Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
    Acta Haematol 117:132-44. 2007
    ..This primary lymphomatous effusion includes human herpes virus 8 (HHV8)-related primary effusion lymphoma (PEL) and HHV8-unrelated PEL-like lymphoma. We attempted to clarify the nature of the primary lymphomatous effusion...
  25. pmc β2 adrenergic agonist attenuates house dust mite-induced allergic airway inflammation through dendritic cells
    Go Kato
    Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5 1 1 Nabeshima, Saga, 849 8501, Japan
    BMC Immunol 15:39. 2014
    ..The aim of this study was to investigate whether LABAs inhibit allergic airway inflammation and how this occurs...
  26. doi request reprint Gangrenous cheilitis associated with all-trans retinoic acid therapy for acute promyelocytic leukemia
    Mariko Tanaka
    Internal Medicine, Saga University, Nabeshima 5 1 1, Saga, 849 8501, Japan
    Int J Hematol 91:132-5. 2010
    ..Physicians should be alert to the development of gangrenous cheilitis during treatment with ATRA...
  27. ncbi request reprint INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity
    Asumi Yokota
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Kyoto, Japan
    Blood 109:306-14. 2007
    ..Furthermore, cyclosporine A, a P-glycoprotein inhibitor, augmented the in vivo activity of INNO-406 against CNS Ph+ leukemia. These findings indicate that INNO-406 is a promising agent for the treatment of CNS Ph+ leukemia...